Johnson & Johnson (NYSE:JNJ) Shares Sold by Wade G W & Inc.

Wade G W & Inc. decreased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 0.9% during the 2nd quarter, Holdings Channel.com reports. The firm owned 154,033 shares of the company’s stock after selling 1,406 shares during the period. Johnson & Johnson accounts for approximately 2.0% of Wade G W & Inc.’s portfolio, making the stock its 12th biggest position. Wade G W & Inc.’s holdings in Johnson & Johnson were worth $21,454,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Northwest Investment Counselors LLC lifted its position in Johnson & Johnson by 0.5% in the fourth quarter. Northwest Investment Counselors LLC now owns 36,568 shares of the company’s stock valued at $4,719,000 after buying an additional 194 shares during the last quarter. First National Trust Co increased its holdings in Johnson & Johnson by 4.8% in the 4th quarter. First National Trust Co now owns 135,826 shares of the company’s stock valued at $17,528,000 after purchasing an additional 6,245 shares during the last quarter. Huntington National Bank increased its holdings in Johnson & Johnson by 18.7% in the 4th quarter. Huntington National Bank now owns 586,823 shares of the company’s stock valued at $75,730,000 after purchasing an additional 92,616 shares during the last quarter. McGuire Investment Group LLC lifted its stake in Johnson & Johnson by 1.4% during the fourth quarter. McGuire Investment Group LLC now owns 26,434 shares of the company’s stock worth $3,411,000 after purchasing an additional 377 shares in the last quarter. Finally, Norris Perne & French LLP MI raised its holdings in shares of Johnson & Johnson by 1.1% in the 4th quarter. Norris Perne & French LLP MI now owns 103,646 shares of the company’s stock valued at $13,376,000 after buying an additional 1,157 shares during the period. Institutional investors own 72.12% of the company’s stock.

Shares of JNJ traded up $1.33 during mid-day trading on Wednesday, reaching $130.88. 2,304,302 shares of the company’s stock were exchanged, compared to its average volume of 7,544,466. The business’s fifty day simple moving average is $130.07 and its 200-day simple moving average is $135.99. The stock has a market capitalization of $335.04 billion, a PE ratio of 16.00, a price-to-earnings-growth ratio of 2.15 and a beta of 0.68. Johnson & Johnson has a 52-week low of $121.00 and a 52-week high of $148.99. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.33 and a quick ratio of 1.04.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, July 16th. The company reported $2.58 earnings per share for the quarter, topping the consensus estimate of $2.42 by $0.16. The business had revenue of $20.56 billion during the quarter, compared to the consensus estimate of $20.39 billion. Johnson & Johnson had a net margin of 20.08% and a return on equity of 38.63%. The business’s quarterly revenue was down 1.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.10 earnings per share. Equities research analysts predict that Johnson & Johnson will post 8.6 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th were issued a $0.95 dividend. The ex-dividend date was Monday, August 26th. This represents a $3.80 annualized dividend and a dividend yield of 2.90%. Johnson & Johnson’s dividend payout ratio is currently 46.45%.

Several brokerages recently weighed in on JNJ. Barclays assumed coverage on shares of Johnson & Johnson in a research note on Friday, June 21st. They set a “hold” rating and a $140.00 target price on the stock. Zacks Investment Research downgraded Johnson & Johnson from a “buy” rating to a “hold” rating and set a $139.00 price target for the company. in a report on Thursday, July 18th. Royal Bank of Canada reiterated a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, July 16th. Goldman Sachs Group set a $169.00 target price on Johnson & Johnson and gave the stock a “buy” rating in a research report on Tuesday, August 27th. Finally, Raymond James decreased their target price on Johnson & Johnson from $147.00 to $146.00 and set an “outperform” rating for the company in a research note on Wednesday, July 17th. Five analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $150.60.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Recommended Story: Why do companies issue monthly dividends?

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.